MARKET

VCYT

VCYT

Veracyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.12
+0.18
+1.06%
Closed 16:31 05/25 EDT
OPEN
16.91
PREV CLOSE
16.94
HIGH
17.78
LOW
16.73
VOLUME
841.52K
TURNOVER
--
52 WEEK HIGH
54.13
52 WEEK LOW
14.85
MARKET CAP
1.22B
P/E (TTM)
-24.8873
1D
5D
1M
3M
1Y
5Y
Veracyte To Present New Data On Co.'s Percepta Nasal Swab Test At American Thoracic Society Event May 17 At 3:30 p.m., 4:30 p.m. EDT
Veracyte, Inc. (NASDAQ:VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history
Benzinga · 05/16 20:52
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
SOUTH SAN FRANCISCO, Calif., May 16, 2022--Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking...
Business Wire · 05/16 20:17
Veracyte Earnings Perspective: Return On Capital Employed
Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million.
Benzinga · 05/13 13:56
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
SOUTH SAN FRANCISCO, Calif., May 12, 2022--Updated AUA/ASTRO Guideline Includes Use of Genomic Tests, Including Decipher Prostate, for Men with Localized Prostate Cancer
Business Wire · 05/12 20:36
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 12, 2022--Veracyte, Inc. (Nasdaq: VCYT) announced today that six abstracts demonstrating the ability of its genomic and immuno-oncology diagnostic tests and technology to improve outcomes for cancer patients will be shared ...
Business Wire · 05/12 12:30
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Despite currently being unprofitable, Veracyte (NASDAQ:VCYT) has delivered a 128% return to shareholders over 5 years
The last three months have been tough on Veracyte, Inc. ( NASDAQ:VCYT ) shareholders, who have seen the share price...
Simply Wall St. · 05/09 18:55
Analyst Ratings for Veracyte
Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings:
Benzinga · 05/04 19:18
More
No Data
Learn about the latest financial forecast of VCYT. Analyze the recent business situations of Veracyte through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
37.50%Buy
12.50%Hold
12.50%Under-perform
0.00%Sell
Analyst Price Target
The average VCYT stock price target is 30.67 with a high estimate of 40.00 and a low estimate of 23.00.
High40.00
Average30.67
Low23.00
Current 17.12
EPS
Actual
Estimate
-0.20-0.15-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 299
Institutional Holdings: 88.51M
% Owned: 123.89%
Shares Outstanding: 71.45M
TypeInstitutionsShares
Increased
76
4.43M
New
26
955.88K
Decreased
66
2.68M
Sold Out
33
1.63M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.02%
Key Executives
Chairman/Executive Director
Bonnie Anderson
Chief Executive Officer/Director
Marc Stapley
Chief Financial Officer
Rebecca Chambers
Corporate Executive
Tina Nova
Senior Vice President/General Counsel
Annie Mcguire
Chief Scientific Officer
Giulia Kennedy
Lead Director/Independent Director
John Bishop
Independent Director
Muna Bhanji
Independent Director
Karin Eastham
Independent Director
Robert Epstein
Independent Director
Kevin Gordon
Independent Director
Jens Holstein
Independent Director
Evan Jones
No Data
No Data
About VCYT
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

Webull offers kinds of Veracyte Inc stock information, including NASDAQ:VCYT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCYT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCYT stock methods without spending real money on the virtual paper trading platform.